Compare the add-on effects in glycemic control and durability of sitagliptin and alfa-glucosidase inhibitor uncontrolled with metformin monotherapy.
Not Applicable
- Conditions
- typw2 diabetes
- Registration Number
- JPRN-UMIN000006630
- Lead Sponsor
- Saitama social insurance hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients who had diabetic ketoacidosis, or diabetic pre- and coma within 6 months of the study entry. 2. Patients who received surgery operation during the study. 3. Patients with pregnancy or Nursing mothers 4. Patients with renal insufficiency (serum creatinine = and > 1.5 mg/dl) 5. Patients who received insulin or GLP-1 analog therapy 6. Patients who received any oral diabetic therapy(exclusive metformin) 7. Patients who had a history of hypersensitivity reaction to sitagliptin 8. Patients whom the attending doctor estimated to be ineligible according to the medical rationale.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HbA1c
- Secondary Outcome Measures
Name Time Method